Effects of KR-30035, a novel multidrug-resistance modulator, on the cardiovascular system of rats in vivo and on the cell cycle of human cancer cells in vitro

Anti-Cancer Drugs

Volumn 11, Issue 1, 2000, Pages 55-61

  Lee, Byung Ho ^a   Shin, Hwa Sup ^a   Lee, Chong Ock ^a   Park, Sung Hee ^a   Yoo, Sung Eun ^a   Yi, Kyu Yang ^a   Jung, Noh Pal ^b   Choi, Sang Un ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

Cardiac toxicity; Cell cycle; KR 30035; Multidrug resistance

Indexed keywords

ARALKYLAMINE; KR 30035; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARDIOTOXICITY; CELL CYCLE; CONTROLLED STUDY; ELECTROCARDIOGRAM; HEART RATE; HUMAN; HUMAN CELL; MALE; MITOSIS INHIBITION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ANTINEOPLASTIC AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR SYSTEM; CELL CYCLE; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FLOW CYTOMETRY; HUMANS; HYPERTENSION; MALE; MICE; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY; TETRAHYDRONAPHTHALENES; TUMOR CELLS, CULTURED; VERAPAMIL;

EID: 0034121438     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200001000-00009     Document Type: Article

References (15)

1. 1. Campling BG, Young LC, Beer KA, et al. Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer. Clin Cancer Res 1997; 3: 115-22.
2. 2. Hyde S, Emsley P, Hartshorn MJ, et al. Structure model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance, and bacterial transport. Nature 1990; 346: 362-5.
3. 3. Harker WG, Bauer D, Etiz BB, Newman RA, Sikic BI. Verapamil-mecliated sensitization of doxorubicin-selected pleiotropic resistance in human sarcoma cells: selectivity for drugs which produce DNA scission. Cancer Res 1986; 46: 2369-73.
4. 4. Benson AB, Trump DL, Koeller JM, et al. Phase I study of vinblastine and verapamil given by concurrent i.v. infusion. Cancer Treat Rep 1985; 69: 795-9.
5. 5. Ozols RF, Cunnion RE, Klecker RW, et al. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 1987; 5: 641-7.
6. 6. Tew KD, Houghton PJ, Houghton JA. Modulation of P-glycoprotein-mediated multidrug resistance. In: Hollinger MA, ed. Preclinical and clinical modulation of anti-cancer drugs. Boca Raton, FL: CRC Press 1983: 125-97.
7. 7. Choi SU, Lee CO, Kim KH, et al. Reversal of multidrug resistance by novel verapamil analogs in cancer cells. Anti-Cancer Drugs 1998; 9: 157-65.
8. 8. Choi SU, Kim NY, Choi EJ, Kim KH, Lee JO. Establishment of doxorubicin-resistant subline derived from HCT15 human colorectal cancer cells. Arch Pharmac Res 1996; 19: 342-7.
9. 9. Lee SH, Jung YS, Lee BH, et al. Characterization of angiotensin II antagonism displayed by SK-1080, a novel nonpepticle AT1-receptor antagonist. J Cardiovasc Pharmacol 1999; 33: 367-74.
10. 10. Lee BH, Seo HW, Kwon KJ, Yoo SE, Shin HS. In vivo pharmacologie profile of SK-1080, an orally active nonpeptide AT1-receptor antagonist. J Cardiovasc Pharmacol 1999; 33: 375-82.
11. 2/M by p53. Oncogene 1995; 10: 109-15.
12. 12. Lui WY, Chang YF, Li LL, et al. Differential paclitaxel-induced cytotoxicity in rodent and human hepatoma cell lines. Anticancer Res 1998; 18: 3339-45.
13. 13. Torres K, Horwitz SB. Mechanisms of taxol-induced cell death are concentration dependent. Cancer Res 1998; 58: 3620-6.
14. 1 phase of growth factor-induced endothelial cell proliferation by various calcium channel blockers. Cancer Detect Prev 1997; 21: 332-9.
15. 15. Nordstrom T, Nevanlinna HA, Andersson LC. Mitosis-arresting effect of the calcium channel inhibitor SK&F 96365 on human leukemia cells. Exp Cell Res 1992; 202: 487-94.